RecallRadar

FDA Drug recall D-0533-2025

Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed…

On 2025-07-23 the FDA classified a Class II recall of Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed… by Ascend Laboratories, citing CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0533-2025
ClassificationClass II
Statusongoing
Initiated2025-07-09
Published2025-07-23
Last updated2026-09-13 11:52 UTC
CompanyAscend Laboratories
DistributionUS

Product

Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-261-18

Reason

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Identifiers

ndc67877-261-30
ndc67877-261-01
ndc67877-261-05
ndc67877-261-18
ndc67877-261-25
ndc67877-262-30
ndc67877-262-01
ndc67877-262-05
ndc67877-262-18
ndc67877-262-25
code_infoLot 23142117, 23142119, 23142122, Exp Date: May 2026; Lot 24142625, Exp Date: Jun. 2027

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0533-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.